Mirion Technologies
MIR
$15.07
+4.65%
Mirion Technologies, Inc. provides products, services, and software that enable customers to safely leverage ionizing radiation across nuclear energy, medical diagnostics, defense, and industrial applications. The company operates through two segments: Nuclear & Safety and Medical, positioning itself as a specialized player in radiation detection and measurement. Currently, the stock is under pressure due to broader market sell-offs and sector-specific headwinds, despite a recent strong quarterly performance with 9.1% revenue growth and improved profitability. Investors are debating whether the company's growth trajectory and margin expansion can offset macroeconomic uncertainties and a high valuation.…
MIR
Mirion Technologies
$15.07
Investment Opinion: Should I buy MIR Today?
Based on the analysis, MIR is rated a Buy. The company's strong Q4 revenue growth of 9.1% YoY, improving margins, and a consensus Strong Buy rating with an average target of $24.70 (66.7% upside) support this view. The forward PE of 22.1x is reasonable for a company with expected EPS growth to $0.79, and the PS ratio of 5.82x is justified by the company's niche market position.
Sign up to view all
MIR 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The company's fundamental performance is strong, with accelerating revenue and margin expansion, and analyst sentiment is highly positive. However, the stock's technical weakness and high valuation on trailing earnings introduce uncertainty. The key factor is whether the company can sustain its growth trajectory to justify the forward PE. If it does, the stock is significantly undervalued. I would upgrade to high confidence if the stock breaks above $20 and maintains growth, and downgrade to neutral if revenue growth falls below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mirion Technologies's 12-month outlook, with a consensus price target around $24.70 and implied upside of +63.9% versus the current price.
Average Target
$24.70
0 analysts
Implied Upside
+63.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$22 - $29
Analyst target range
Mirion is covered by 10 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.4). The average price target is $24.70, implying a substantial upside of 66.7% from the current price of $14.82. The distribution of ratings is overwhelmingly bullish, with no sell ratings and only a few hold ratings, indicating strong conviction among analysts. This optimism is supported by the company's recent earnings beat and positive outlook for the nuclear and medical sectors.
Bulls vs Bears: MIR Investment Factors
Mirion presents a classic growth-versus-value tension. On the bull side, the company is executing well operationally, with accelerating revenue growth, expanding margins, and a strong analyst consensus. On the bear side, the stock's valuation is stretched on trailing earnings, and the market has punished the shares severely, reflecting skepticism about sustainability. The most critical factor is whether the company can maintain its growth trajectory and margin expansion to justify the forward PE of 22x. If it does, the stock is significantly undervalued relative to the $24.70 average target. If growth falters, the stock could test its 52-week low. Currently, the evidence slightly favors the bulls given the fundamental momentum, but the technical weakness and high valuation warrant caution.
Bullish
- Strong Q4 revenue growth: Q4 2025 revenue grew 9.1% YoY to $277.4M, with sequential acceleration from $223.1M in Q3. This indicates robust demand in nuclear and medical end markets, supporting the company's growth narrative.
- Margin expansion trend: Gross margin improved to 48.8% in Q4 2025 from 46.1% in Q2 2025, and operating margin rose to 9.2% from 4.4% in Q2. This demonstrates operational leverage and cost discipline, driving profitability higher.
- Analyst consensus Strong Buy: 10 analysts rate MIR a Strong Buy with a mean rating of 1.4 and an average price target of $24.70, implying 66.7% upside. No sell ratings and only a few holds indicate high conviction in the company's prospects.
- Positive earnings trajectory: The company turned profitable in 2025, with Q4 EPS of $0.07 and full-year positive net income, reversing losses from 2024. Forward PE of 22.1x suggests the market expects continued earnings growth, supported by analyst EPS estimates of $0.79 for the next year.
Bearish
- Severe stock underperformance: MIR is down 26.7% over the past year and 30.4% over six months, while the S&P 500 gained 20.5% and 11.1% respectively. This persistent underperformance signals weak investor sentiment and potential structural issues.
- High valuation on trailing earnings: Trailing PE is 180.2x, extremely elevated even for a growth stock. This leaves little room for error; any earnings miss could trigger a sharp de-rating, as seen in the stock's 51% drawdown from its 52-week high.
- Near 52-week low with negative momentum: The stock trades at $14.82, only 4.7% above its 52-week low of $14.11. With a 1-month decline of 10.7% and negative relative strength of -13.1% vs. the S&P 500, technicals suggest continued downside risk.
- High short interest and low liquidity: Short ratio is 8.33 days to cover, indicating significant bearish positioning. This could exacerbate downside moves if negative news emerges, as short sellers may press their advantage.
MIR Technical Analysis
Mirion's stock is in a pronounced downtrend, with a 1-year price change of -26.67% and a 6-month decline of -30.36%. The current price of $14.82 sits near the 52-week low of $14.11, representing only 4.7% above the low and 51.1% below the 52-week high of $30.28. This positioning near the lows suggests persistent selling pressure and a lack of buyer conviction, though it may also indicate a potential value opportunity if fundamentals stabilize.
Beta
1.06
1.06x market volatility
Max Drawdown
-51.6%
Largest decline past year
52-Week Range
$14-$30
Price range past year
Annual Return
-26.5%
Cumulative gain past year
| Period | MIR Return | S&P 500 |
|---|---|---|
| 1m | +0.6% | +2.7% |
| 3m | -16.5% | +1.0% |
| 6m | -30.2% | +12.0% |
| 1y | -26.5% | +18.9% |
| ytd | -36.8% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MIR Fundamental Analysis
Mirion's revenue has shown solid growth, with Q4 2025 revenue of $277.4 million, up 9.08% year-over-year, and a sequential increase from $223.1 million in Q3 2025. The company's product segment generated $166.1 million in revenue, while services contributed $57.0 million, indicating a diversified revenue stream. However, the growth rate has been uneven, with Q1 2025 revenue of $202.0 million and Q2 2025 revenue of $222.9 million, suggesting some quarter-to-quarter volatility. The overall trend is positive, with full-year 2025 revenue likely exceeding 2024's $861 million, driven by strength in nuclear and medical end markets.
Quarterly Revenue
$277400000.0B
2025-12
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
48.8%
Latest Quarter
Free Cash Flow
$107400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MIR Overvalued?
Given that Mirion has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 180.15x, while the forward PE is 22.08x, indicating that the market expects significant earnings growth. This wide gap between trailing and forward earnings suggests that the market is pricing in a substantial improvement in profitability, which is supported by the company's recent margin expansion. The PEG ratio is negative at -1.05, which is not meaningful due to the low current earnings base.
PE
180.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 60x~450x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are notable. Mirion carries a debt-to-equity ratio of 0.66, which is manageable but not negligible, and interest expenses of $9M in Q4 2025 consume a portion of operating income. The company's net margin is thin at 3.1% (TTM), leaving limited cushion for operational hiccups. Free cash flow is positive at $107.4M TTM, but the high trailing PE of 180x means the stock price relies heavily on future earnings growth; any disappointment could lead to a sharp de-rating. Additionally, the company's revenue growth has been uneven, with Q1 2025 revenue of $202M and Q2 of $222.9M, indicating quarter-to-quarter volatility that could unsettle investors.